Theratechnologies, Merck KGaA deal

Theratechnologies will regain U.S. rights to Egrifta tesamorelin from Merck's EMD Serono Inc. subsidiary for $20 million after the partners agreed to terminate their 2008 deal. Theratechnologies will pay the $20 million in equal payments to Merck over a five-year period beginning